La conférence est annulée en raison des restrictions sanitaires.
Le Professeur Jean-Yves WINUM de l’Institut des Biomolécules Max Mousseron à Montpellier (IBMM) donnera le 18 décembre 2020 une conférence au CEISAM sur les inhibiteurs de l’anhydrase carbonique en tant que potentiel agents anti-cancéreux et anti-infectieux.
Résumé de la conférence :
Carbonic anhydrases (CAs, EC.184.108.40.206) are ubiquitous zinc metalloproteins, found in most eukaryotic and prokaryotic organisms, which catalyze efficiently the reversible hydration of carbon dioxide to bicarbonate with release of a proton. CA have been extensively studied as potential drug targets for therapeutic intervention in various diseases such as cancer, and recently in infectious diseases. In the past decades, a large category of diverse families of CA inhibitors (CAIs) have been developed and many of them showed effective inhibition toward specific isoforms, and effectiveness in pathological conditions in preclinical and clinical settings. The discovery of isoform-selective CAIs in the last decade led to diminished side effects associated with off-target isoforms inhibition.
This conference is intended to highlight our input in the search of new and effective modulators of these enzymes acting via new mechanisms of action. Different discovered classes of inhibitors show promise for designing interesting pharmacological agents and understanding in detail protein-drug interactions at molecular level.
- Carta F, Dumy P, Supuran CT, Winum JY. Multivalent Carbonic Anhydrases Inhibitors. Int J Mol Sci. 2019, 20, 5352.
- Nocentini A, Supuran CT, Winum JY. Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018). Expert Opin Ther Pat. 2018, 28, 493-504.
- Supuran CT, Winum JY Carbonic anhydrase IX inhibitors in cancer therapy: an update. Future Med Chem. 2015, 7, 1407-14.